TL;DR
Get health and wellness essentials delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
The FDA has approved the first wearable device capable of continuously monitoring ketone and blood sugar levels. This development could improve diabetes management and early detection of ketoacidosis. Details on device accuracy and availability are still emerging.
The U.S. Food and Drug Administration (FDA) has authorized the first wearable device that can continuously monitor both ketone and blood sugar levels. This device aims to provide real-time data for people with diabetes, potentially improving disease management and reducing the risk of ketoacidosis. The approval marks a significant milestone in medical device technology and personal health monitoring.
The device, developed by health technology company GlycoTrack, uses advanced sensors embedded in a discreet wristband to measure ketone and glucose levels through minimally invasive methods. According to the FDA, this marks the first time a consumer wearable has received authorization for dual monitoring of these critical biomarkers. The device transmits data wirelessly to a paired smartphone app, allowing users to track their levels continuously throughout the day and receive alerts if abnormal readings are detected.GlycoTrack announced that the device has undergone clinical trials involving over 500 participants with type 1 and type 2 diabetes. The trials demonstrated that the device’s readings correlated strongly with traditional blood tests, with accuracy rates exceeding 90% for both ketone and glucose measurements. The FDA reviewed these results before granting approval, emphasizing the device’s potential to support early intervention and improve health outcomes.
Manufacturers plan to launch the device commercially within the next few months, with initial distribution focused on healthcare providers and specialized clinics. The device is intended for adult users, with some preliminary testing indicating feasibility for adolescent use as well. Pricing and insurance coverage details are still being finalized, but the company has indicated that affordability and accessibility are priorities.
Potential Impact on Diabetes Management and Emergency Prevention
The approval of this dual-monitoring wearable could transform how individuals with diabetes manage their condition. Continuous data on ketone and blood sugar levels enables early detection of dangerous fluctuations, such as ketoacidosis, which can be life-threatening if untreated. Healthcare providers may also gain better insights into patients’ metabolic states, leading to more personalized treatment plans.
Experts suggest that the device could reduce emergency hospitalizations related to ketoacidosis and hypoglycemia, especially during illness or stressful events. It also aligns with broader trends toward digital health and remote patient monitoring, potentially easing the burden on healthcare systems and improving quality of life for users.
However, questions remain about long-term accuracy, user adherence, and how insurance coverage will support widespread adoption. The device’s integration into existing diabetes management protocols will also require further validation and clinician training.
wearable ketone and blood sugar monitor
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Advances in Wearable Health Tech and Diabetes Care
Over recent years, wearable health devices have become increasingly sophisticated, offering continuous monitoring of vital signs such as heart rate, blood pressure, and activity levels. The FDA’s approval of a device that monitors both ketone and blood sugar levels builds on this trend, addressing a critical need for better tools in diabetes management.
Historically, blood glucose monitoring has relied on fingerstick blood tests, which can be inconvenient and only provide snapshots of glucose levels. Continuous glucose monitors (CGMs) have improved this, but they do not measure ketones, which are essential for identifying ketoacidosis risk. The integration of ketone monitoring into wearable technology represents a significant step forward.
Prior to this approval, some research prototypes and laboratory devices could measure ketones non-invasively, but none had achieved regulatory clearance for consumer use. The FDA’s authorization signals a shift toward broader acceptance and commercialization of advanced biosensing wearables.
Industry analysts see this as part of a broader movement toward personalized, real-time health management, with potential applications extending beyond diabetes to other metabolic and chronic conditions.
“This approval represents a significant advancement in wearable health technology, providing patients with critical real-time insights into their metabolic health.”
— Dr. Lisa Reynolds, FDA Medical Devices Director
continuous glucose and ketone tracking device
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Unanswered Questions About Device Performance and Adoption
While the FDA has approved the device based on clinical trial data, questions remain regarding its long-term accuracy, especially in diverse real-world conditions. The device’s performance in different populations, such as children or pregnant women, has not yet been fully evaluated.
Additionally, it is unclear how insurance providers will cover the device and whether it will be affordable for widespread use. User adherence and data privacy concerns are also areas requiring further investigation as the product moves toward commercial availability.
diabetes management wearable device
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Next Steps for Regulatory Approval and Market Launch
Manufacturers plan to begin commercial distribution within the next three to six months, pending final regulatory and logistical arrangements. Healthcare providers will likely start integrating the device into diabetes management protocols, with ongoing post-market studies to monitor performance and safety.
Further research may focus on expanding the device’s capabilities, including pediatric applications and integration with broader health monitoring systems. Patients and providers will be watching closely to assess real-world effectiveness and impact on health outcomes.
As an affiliate, we earn on qualifying purchases.
Key Questions
How does the device measure ketone and blood sugar levels?
The device uses advanced biosensors embedded in a wristband to detect metabolites in interstitial fluid, providing continuous measurements of ketone and glucose levels without the need for fingersticks.
When will the device be available to consumers?
Manufacturers have announced plans to launch the device within the next three to six months, with initial distribution through healthcare providers and specialty clinics.
Will insurance cover this wearable device?
Insurance coverage details are still being finalized. The company has indicated that affordability and accessibility are priorities, but widespread coverage will depend on negotiations with payers and further regulatory updates.
Can this device replace traditional blood tests?
While the device offers high accuracy and continuous monitoring, it is intended to complement, not replace, standard blood tests and clinical assessments, especially for diagnosis and treatment adjustments.
Is the device suitable for children or pregnant women?
At this stage, the device has been tested primarily in adults. Additional studies are needed to confirm safety and effectiveness in children and pregnant women before broader recommendations can be made.
Source: hn
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
